Company news
Jupiter Neurosciences, Inc. news in 2026
Jupiter Neurosciences, Inc.'s news releases, calls and decks from 2026, newest first.
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
October 6, 2026
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
August 5, 2026
Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
July 22, 2026
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
July 21, 2026
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
July 6, 2026
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
May 26, 2026
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq: JUNS) in Connection with its ~$2 Million Registered Direct Offering
May 26, 2026
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
May 20, 2026
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
May 20, 2026
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
May 20, 2026
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
May 4, 2026
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
April 12, 2026
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
April 6, 2026
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
March 30, 2026
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
March 1, 2026
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
February 25, 2026
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
February 23, 2026
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
January 28, 2026
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
January 27, 2026
Decks in 2026
- Investor Presentation (April 2026)
Investor deck · 14 slides · Apr 2, 2026